ArticleDrug safety2026
The Extent and Magnitude of Bias in Case-Crossover Studies of Real-World Non-transient Medications Patterns: A Simulation Study with Real-World Examples.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA case-crossover study is a self-controlled design most appropriate for evaluating transient medication exposures. However, it has increasingly been used in studies of chronic medications and can cause bias in effect estimates that vary based on the pattern of medication use. The goal of this study was to evaluate the magnitude of this bias across different medication-use patterns.
objectiveTo quantify the magnitude of the bias introduced by different medication patterns and evaluate different case-crossover approaches to mitigate the bias.
methodsWe conducted a simulation study evaluating the bias introduced by (1) seven common medication patterns separately, and (2) cohort with 15 different patterns combined. We evaluated each scenario under risk ratios of 0.50, 0.75, 1.00, 1.50, and 2.00. Each approach was analyzed using conditional logistic regression comparing the probability of exposure on the outcome day to 30 days prior. A case-time-control design was used in each of the scenarios. Sensitivity analysis was performed to evaluate the impact on the estimates when changing the length of the risk and control windows. We conducted a real-world example focusing on sodium-glucose co-transporter-2 inhibitor users as real-world examples.
resultsThe case-crossover design resulted in unbiased estimates when patterns were consistent with transient exposures but were biased upward with prolonged exposure patterns. The magnitude of the bias varies by patterns or pattern combinations. When evaluating prolonged exposures individually or combined as a cohort with mixture patterns, case-time-control with extended risk and control window (30 days) produced unbiased results (mean bias ≤ 0.03).
conclusionResearchers who use the case-crossover design to evaluate non-transient exposures should implement recommended methods to account for biases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.